Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma

BACKGROUND: Cabozantinib improved progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) compared with everolimus in patients with advanced renal cell carcinoma (RCC) after prior antiangiogenic therapy in the phase III METEOR trial (NCT01865747). Limited data are av...

Descripción completa

Detalles Bibliográficos
Autores principales: Donskov, Frede, Motzer, Robert J., Voog, Eric, Hovey, Elizabeth, Grüllich, Carsten, Nott, Louise M., Cuff, Katharine, Gil, Thierry, Jensen, Niels Viggo, Chevreau, Christine, Negrier, Sylvie, Depenbusch, Reinhard, Bergmann, Lothar, Cornelio, Izzy, Champsaur, Anne, Escudier, Bernard, Pal, Sumanta, Powles, Thomas, Choueiri, Toni K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521477/
https://www.ncbi.nlm.nih.gov/pubmed/31887537
http://dx.doi.org/10.1016/j.ejca.2019.10.032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521477/
https://www.ncbi.nlm.nih.gov/pubmed/31887537
http://dx.doi.org/10.1016/j.ejca.2019.10.032

Ejemplares similares